hemodialysis patients
Conditions
Interventions
We administer to the patients levocarnitine 1000 mg/dose during every dialysis for 3 months and compare with the sedentary group.
We administer to the patients levocarnitine 1000 mg/dose during every
Sponsors
Tsukuba University of technology
Hirayama hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Disease stage is Stage 5 CKD. 2. Physical status is long-term care level 3 or higher (even if prior to official receipt of care level certification). 3. Patients who have provided their informed written consent to participation in the study.
Exclusion criteria
Exclusion criteria: 1. Patients presenting with unstable angina, acute phase acute coronary syndrome, hemodynamic instability, or resting SpO2 lower than 90. 2. Patients exhibiting a marked decline in cognitive functions, patients wearing pacemaker devices, or pregnant women. 3. Other patients deemed by a physician to be otherwise unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Physical activity | — |
Secondary
| Measure | Time frame |
|---|---|
| biochemical effects | — |
Countries
Japan
Contacts
Public ContactAki Hirayama
Tsukuba University of technology Faculty of Health Sciences
Outcome results
None listed